Frank Yocca - Mar 14, 2022 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Scientific Officer
Signature
/s/ Javier Rodriguez, as Attorney-in-Fact for Frank Yocca, Ph.D.
Stock symbol
BTAI
Transactions as of
Mar 14, 2022
Transactions value $
$0
Form type
4
Date filed
3/16/2022, 04:15 PM
Next filing
Jan 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Award $0 +8.34K $0.00 8.34K Mar 14, 2022 Common Stock 8.34K Direct F1, F2
transaction BTAI Stock Option (Right to Buy) Award $0 +33.4K $0.00 33.4K Mar 14, 2022 Common Stock 33.4K $15.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.